Tags

Type your tag names separated by a space and hit enter

Management of paraneoplastic neurological syndromes: report of an EFNS Task Force.
Eur J Neurol 2006; 13(7):682-90EJ

Abstract

Paraneoplastic neurological syndromes (PNS) are remote effects of cancer on the nervous system. An overview of the management of classical PNS, i.e. paraneoplastic limbic encephalitis, subacute sensory neuronopathy, paraneoplastic cerebellar degeneration, paraneoplastic opsoclonus-myoclonus, Lambert-Eaton myasthenic syndrome and paraneoplastic peripheral nerve hyperexcitability is given. Myasthenia gravis and paraproteinemic neuropathies are not included in this report. No evidence-based recommendations were possible, but good practice points were agreed by consensus. Urgent investigation is indicated, especially in central nervous system (CNS) syndromes, to allow tumour therapy to be started early and prevent progressive neuronal death and irreversible disability. Onconeural antibodies are of great importance in the investigation of PNS and can be used to focus tumour search. PDG-PET is useful if the initial radiological tumour screen is negative. Early detection and treatment of the tumour is the approach that seems to offer the greatest chance for PNS stabilization. Immune therapy usually has no or modest effect on the CNS syndromes, whereas such therapy is beneficial for PNS affecting the neuromuscular junction. Symptomatic therapy should be offered to all patients with PNS.

Authors+Show Affiliations

Department of Neurology, Haukeland University Hospital, Bergen, Norway. christian.vedeler@helse-bergen.noNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

16834698

Citation

Vedeler, C A., et al. "Management of Paraneoplastic Neurological Syndromes: Report of an EFNS Task Force." European Journal of Neurology, vol. 13, no. 7, 2006, pp. 682-90.
Vedeler CA, Antoine JC, Giometto B, et al. Management of paraneoplastic neurological syndromes: report of an EFNS Task Force. Eur J Neurol. 2006;13(7):682-90.
Vedeler, C. A., Antoine, J. C., Giometto, B., Graus, F., Grisold, W., Hart, I. K., ... Voltz, R. (2006). Management of paraneoplastic neurological syndromes: report of an EFNS Task Force. European Journal of Neurology, 13(7), pp. 682-90.
Vedeler CA, et al. Management of Paraneoplastic Neurological Syndromes: Report of an EFNS Task Force. Eur J Neurol. 2006;13(7):682-90. PubMed PMID: 16834698.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Management of paraneoplastic neurological syndromes: report of an EFNS Task Force. AU - Vedeler,C A, AU - Antoine,J C, AU - Giometto,B, AU - Graus,F, AU - Grisold,W, AU - Hart,I K, AU - Honnorat,J, AU - Sillevis Smitt,P A E, AU - Verschuuren,J J G M, AU - Voltz,R, AU - ,, PY - 2006/7/13/pubmed PY - 2006/8/24/medline PY - 2006/7/13/entrez SP - 682 EP - 90 JF - European journal of neurology JO - Eur. J. Neurol. VL - 13 IS - 7 N2 - Paraneoplastic neurological syndromes (PNS) are remote effects of cancer on the nervous system. An overview of the management of classical PNS, i.e. paraneoplastic limbic encephalitis, subacute sensory neuronopathy, paraneoplastic cerebellar degeneration, paraneoplastic opsoclonus-myoclonus, Lambert-Eaton myasthenic syndrome and paraneoplastic peripheral nerve hyperexcitability is given. Myasthenia gravis and paraproteinemic neuropathies are not included in this report. No evidence-based recommendations were possible, but good practice points were agreed by consensus. Urgent investigation is indicated, especially in central nervous system (CNS) syndromes, to allow tumour therapy to be started early and prevent progressive neuronal death and irreversible disability. Onconeural antibodies are of great importance in the investigation of PNS and can be used to focus tumour search. PDG-PET is useful if the initial radiological tumour screen is negative. Early detection and treatment of the tumour is the approach that seems to offer the greatest chance for PNS stabilization. Immune therapy usually has no or modest effect on the CNS syndromes, whereas such therapy is beneficial for PNS affecting the neuromuscular junction. Symptomatic therapy should be offered to all patients with PNS. SN - 1468-1331 UR - https://www.unboundmedicine.com/medline/citation/16834698/Management_of_paraneoplastic_neurological_syndromes:_report_of_an_EFNS_Task_Force_ L2 - https://doi.org/10.1111/j.1468-1331.2006.01266.x DB - PRIME DP - Unbound Medicine ER -